Drug Type Bispecific antibody |
Synonyms CD40xFAP Bispecific (Bristol Myers Squibb), BMS 986484, BMS986484 |
Target |
Action inhibitors, antagonists |
Mechanism CD40 inhibitors(Tumor necrosis factor receptor superfamily member 5 inhibitors), FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 10 Oct 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 10 Oct 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Canada | 10 Oct 2024 |






